May 7, 2008 - VioQuest Pharmaceuticals (OTCBB:VOQP) today announced that the United States Patent and Trademark Office has issued a patent for the company's investigational product candidate Xyfid(TM) (1% topical uracil). U.S. Patent No. 7,368,456 ('456 patent), entitled "Methods, compositions, and kits for organ protection during systemic anticancer therapy," includes pharmaceutical compositions, methods of treatment, and combination kits. The '456 patent applies to the use of Xyfid as well as to a range of methods designed to protect body tissue from the toxic effects of certain systemically administered anticancer therapeutic agents.
In particular, cutaneous toxicities are a side effect associated with some commonly used anticancer therapies, including epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, 5-fluorouracil (5-FU), and the oral 5-FU prodrug capecitabine.
No comments:
Post a Comment